SCHEMBL14211570

SCHEMBL14211570

CC(=O)Cc1cc(-c2ccc(C)cc2)n(C(C)=O)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
KDM5A P29375 2/20 0.40
KDM4C Q9H3R0 2/20 0.40
KDM5B Q9UGL1 2/20 0.40
PTGS2 P35354 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38
TUBA1A Q71U36 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3501586 0.77 ADORA3 (0.50) NR1H2NR1H3PTGS2TUBB4ATUBB
SCHEMBL17280011 0.66 STAT3 (0.50) NR1H2NR1H3PTGS2RAB9ASMN1; SMN2
SCHEMBL3500988 0.65 TUBB4A (0.59) NR1H2NR1H3KDM5AKDM4CKDM5B
SCHEMBL24409055 0.64 NR1H4 (0.74) SMN1; SMN2NPC1MEN1KMT2ARXRA
SCHEMBL14728118 0.62 RXRA (0.80) PTGS2CA1CA2CA9CCKAR
SCHEMBL7229581 0.62 RAB9A (0.44) RAB9AHDAC6SMN1; SMN2NPC1MEN1
SCHEMBL20866506 0.62 NR1H2 (0.46) NR1H2NR1H3KDM4EPOLBRPA1
SCHEMBL12177119 0.62 CA1 (0.76) PTGS2CA1CA2CA9CCKAR
SCHEMBL17279868 0.62 STAT3 (0.47) NR1H2NR1H3PTGS2RAB9ASMN1; SMN2
SCHEMBL13703227 0.62 KDM5A (0.48) KDM5AKDM4CKDM5BPTGS2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673940-B2 Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins AC IMMUNE SA (CH) 2014-03-18 US disclosed
US-20120309791-A1 NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2012-12-06 US disclosed
WO-2008061795-A2 N- (METHYL) -1H- PYRAZOL- 3 -AMINE, N- (METHYL) -PYRIDIN-2-AMINE AND N- (METHYL) -THIAZ0L-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S AC IMMUNE SA (CH) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309791-A1 NOVEL COMPOUND FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS APP, PSEN2, PSEN1 NR1H2 142/4885NR1H3 178/4885KDM5A 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.